Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Monnier

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Journal of Diabetes Science and Technology|May 31, 2014
Self-monitoring of blood glucose: a prerequisite for diabetes management in outcome trialsOliver Schnell, Markolf Hanefeld, Louis Monnier
Journal of Diabetes Science and Technology|November 4, 2009
Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?Louis Monnier, Claude Colette, David R Owens
Diabetes/Metabolism Research and Reviews|May 14, 2009
Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad conceptLouis Monnier, Claude Colette, David R Owens
Diabetes/Metabolism Research and Reviews|September 13, 2013
Basal insulin analogues in the management of diabetes mellitus: What progress have we made?David R Owens, Glenn Matfin, Louis Monnier
Diabetes, Obesity & Metabolism|May 6, 2017
A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitusDavid R Owens, Louis Monnier, Markolf Hanefeld
Diabetes, Obesity & Metabolism|April 23, 2017
Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapyDavid R Owens, Louis Monnier, Anthony H Barnett
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 11, 2016
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsMarkolf Hanefeld, Louis Monnier, Oliver Schnell, et al.
Diabetes Technology & Therapeutics|May 13, 2011
The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetesLouis Monnier, Anne Wojtusciszyn, Claude Colette, et al.
Diabetes Care|October 31, 2013
Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?Louis Monnier, Claude Colette, Sylvie Dejager, et al.
Diabetes & Metabolism|October 1, 2020
The obesity treatment dilemma: Why dieting is both the answer and the problem? A mechanistic overviewLouis Monnier, Jean-Louis Schlienger, Claude Colette, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Journal of Diabetes Science and Technology|May 31, 2014
Self-monitoring of blood glucose: a prerequisite for diabetes management in outcome trialsOliver Schnell, Markolf Hanefeld, Louis Monnier
Journal of Diabetes Science and Technology|November 4, 2009
Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?Louis Monnier, Claude Colette, David R Owens
Diabetes/Metabolism Research and Reviews|May 14, 2009
Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad conceptLouis Monnier, Claude Colette, David R Owens
Diabetes/Metabolism Research and Reviews|September 13, 2013
Basal insulin analogues in the management of diabetes mellitus: What progress have we made?David R Owens, Glenn Matfin, Louis Monnier
Diabetes, Obesity & Metabolism|May 6, 2017
A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitusDavid R Owens, Louis Monnier, Markolf Hanefeld
Diabetes, Obesity & Metabolism|April 23, 2017
Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapyDavid R Owens, Louis Monnier, Anthony H Barnett
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 11, 2016
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsMarkolf Hanefeld, Louis Monnier, Oliver Schnell, et al.
Diabetes Technology & Therapeutics|May 13, 2011
The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetesLouis Monnier, Anne Wojtusciszyn, Claude Colette, et al.
Diabetes Care|October 31, 2013
Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?Louis Monnier, Claude Colette, Sylvie Dejager, et al.
Diabetes & Metabolism|October 1, 2020
The obesity treatment dilemma: Why dieting is both the answer and the problem? A mechanistic overviewLouis Monnier, Jean-Louis Schlienger, Claude Colette, et al.
Pageof 5